MAGENTIQ EYE Secures Series A Funding to Transform Gastroenterology
MAGENTIQ EYE LTD., renowned for its cutting-edge AI-powered decision-support software in gastroenterology, has successfully closed its Series A investment round. This funding, primarily led by aMoon, is poised to accelerate the commercialization of its renowned MAGENTIQ-COLO™ software across various regions.
Significant Advances in AI Technology
The MAGENTIQ-COLO™ software, which has received FDA and CE approvals, is engineered to significantly enhance polyp detection and analysis during colonoscopies. By improving adenoma detection rates, it aims to provide real-time insights that help clinicians make informed decisions during procedures. This innovative tool includes advanced features such as polyp size categorization and type estimation, alongside AI-generated reports that streamline the diagnostic process.
Investment Details and Future Plans
This Series A funding round attracted major players in the investment landscape, including Norgine Ventures BV, Nina Capital, and private investors. The round also saw aMoon's partner, Roy Wiesner, joining the board of directors, contributing valuable strategic insight and extensive experience in the health tech industry.
Dror Zur, Ph.D., the founder and CEO of MAGENTIQ EYE, expressed excitement over the investment. "This is a pivotal moment in our journey as we partner with aMoon. Their support allows us to speed up innovation and expand our reach to more patients and physicians, responding to the burgeoning demand for our technologies," he stated.
Strong Market Interest
Wiesner emphasized the unique position of MAGENTIQ EYE in the market, commenting on its comprehensive features and cost-effective scalability. He noted the growing interest from key strategic partners, underlining their confidence in the solution's potential to improve patient outcomes significantly.
Ongoing Clinical Trials and Development
MAGENTIQ EYE is actively conducting clinical trials targeting specialized diseases in both the lower and upper gastrointestinal tract. These include conditions such as ulcerative colitis and early dysplasia in Barrett's esophagus. The funding will enable them to further develop automated quality indicators for GI procedures, enhancing the overall diagnostic tools in their portfolio.
The company aims to leverage this investment to foster growth not just in the U.S. but also in European markets, establishing new partnerships and expanding existing operations to fulfill the demanding landscape of health technology.
About MAGENTIQ EYE
Founded in 2014, MAGENTIQ EYE is dedicated to revolutionizing colonoscopy procedures with its AI-aided solutions. The company has earned recognition in the gastroenterology community and continually strives to set new standards in the field, performing numerous procedures daily with the aid of its flagship product, MAGENTIQ-COLO™.
About aMoon
aMoon is a prominent health tech and life sciences venture capital firm located in Israel, managing an impressive $1.3 billion in assets. The fund aims to support innovative technologies and scientific breakthroughs that can transform healthcare, partnering with visionary entrepreneurs to advance their missions.
Frequently Asked Questions
1. What is MAGENTIQ EYE known for?
MAGENTIQ EYE is recognized for its AI-powered software that enhances decision-making in gastroenterology, particularly in improving colonoscopy outcomes.
2. Who led the Series A funding for MAGENTIQ EYE?
The Series A funding round was primarily led by aMoon, a major HealthTech investment fund focused on innovative solutions in healthcare.
3. What capabilities does MAGENTIQ-COLO™ offer?
MAGENTIQ-COLO™ provides advanced features for polyp detection, size categorization, and AI-generated reports to improve colonoscopy procedures.
4. Which conditions are targeted through MAGENTIQ EYE's clinical trials?
The clinical trials are focusing on diseases like ulcerative colitis, early dysplasia in Barrett's esophagus, and gastric intestinal metaplasia.
5. How will the funding benefit MAGENTIQ EYE?
The funding will support the development of advanced diagnostic tools and enable the company to expand its commercial growth in various global markets, including the USA and Europe.
